BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 23661576)

  • 1. CD133 expression in circulating tumor cells from breast cancer patients: potential role in resistance to chemotherapy.
    Nadal R; Ortega FG; Salido M; Lorente JA; Rodríguez-Rivera M; Delgado-Rodríguez M; Macià M; Fernández A; Corominas JM; García-Puche JL; Sánchez-Rovira P; Solé F; Serrano MJ
    Int J Cancer; 2013 Nov; 133(10):2398-407. PubMed ID: 23661576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinct expression of cytokeratin, N-cadherin and CD133 in circulating tumor cells of metastatic breast cancer patients.
    Bock C; Rack B; Huober J; Andergassen U; Jeschke U; Doisneau-Sixou S
    Future Oncol; 2014 Aug; 10(10):1751-65. PubMed ID: 25303055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phenotypic characterization of circulating tumor cells in triple negative breast cancer patients.
    Agelaki S; Dragolia M; Markonanolaki H; Alkahtani S; Stournaras C; Georgoulias V; Kallergi G
    Oncotarget; 2017 Jan; 8(3):5309-5322. PubMed ID: 28029660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Twist1 expression induced by sunitinib accelerates tumor cell vasculogenic mimicry by increasing the population of CD133+ cells in triple-negative breast cancer.
    Zhang D; Sun B; Zhao X; Ma Y; Ji R; Gu Q; Dong X; Li J; Liu F; Jia X; Leng X; Zhang C; Sun R; Chi J
    Mol Cancer; 2014 Sep; 13():207. PubMed ID: 25200065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarkers characterization of circulating tumour cells in breast cancer patients.
    Nadal R; Fernandez A; Sanchez-Rovira P; Salido M; Rodríguez M; García-Puche JL; Macià M; Corominas JM; Delgado-Rodriguez M; Gonzalez L; Albanell J; Fernández M; Solé F; Lorente JA; Serrano MJ
    Breast Cancer Res; 2012 May; 14(3):R71. PubMed ID: 22554015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes' stage B and C colorectal cancer.
    Iinuma H; Watanabe T; Mimori K; Adachi M; Hayashi N; Tamura J; Matsuda K; Fukushima R; Okinaga K; Sasako M; Mori M
    J Clin Oncol; 2011 Apr; 29(12):1547-55. PubMed ID: 21422427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer stem cell markers are enriched in normal tissue adjacent to triple negative breast cancer and inversely correlated with DNA repair deficiency.
    Atkinson RL; Yang WT; Rosen DG; Landis MD; Wong H; Lewis MT; Creighton CJ; Sexton KR; Hilsenbeck SG; Sahin AA; Brewster AM; Woodward WA; Chang JC
    Breast Cancer Res; 2013; 15(5):R77. PubMed ID: 24008095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer.
    Ignatiadis M; Xenidis N; Perraki M; Apostolaki S; Politaki E; Kafousi M; Stathopoulos EN; Stathopoulou A; Lianidou E; Chlouverakis G; Sotiriou C; Georgoulias V; Mavroudis D
    J Clin Oncol; 2007 Nov; 25(33):5194-202. PubMed ID: 17954712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heterogeneous atypical cell populations are present in blood of metastatic breast cancer patients.
    Lustberg MB; Balasubramanian P; Miller B; Garcia-Villa A; Deighan C; Wu Y; Carothers S; Berger M; Ramaswamy B; Macrae ER; Wesolowski R; Layman RM; Mrozek E; Pan X; Summers TA; Shapiro CL; Chalmers JJ
    Breast Cancer Res; 2014 Mar; 16(2):R23. PubMed ID: 24602188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD133+ cells with cancer stem cell characteristics associates with vasculogenic mimicry in triple-negative breast cancer.
    Liu TJ; Sun BC; Zhao XL; Zhao XM; Sun T; Gu Q; Yao Z; Dong XY; Zhao N; Liu N
    Oncogene; 2013 Jan; 32(5):544-53. PubMed ID: 22469978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In triple negative breast tumor cells, PLC-β2 promotes the conversion of CD133high to CD133low phenotype and reduces the CD133-related invasiveness.
    Brugnoli F; Grassilli S; Piazzi M; Palomba M; Nika E; Bavelloni A; Capitani S; Bertagnolo V
    Mol Cancer; 2013 Dec; 12():165. PubMed ID: 24330829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Detection and clinical significance of circulating tumor cells in peripheral blood of breast cancer patients].
    Cai QQ; Huang HQ; Lin TX; Jiang WQ
    Ai Zheng; 2005 Jul; 24(7):837-41. PubMed ID: 16004811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of circulating tumor cells during follow-up of patients with early breast cancer: Clinical utility for monitoring of therapy efficacy.
    Mikulová V; Cabiňaková M; Janatková I; Mestek O; Zima T; Tesařová P
    Scand J Clin Lab Invest; 2014 Mar; 74(2):132-42. PubMed ID: 24350991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of invasive properties of CD133+ glioblastoma stem cells: a role for MT1-MMP in bioactive lysophospholipid signaling.
    Annabi B; Lachambre MP; Plouffe K; Sartelet H; Béliveau R
    Mol Carcinog; 2009 Oct; 48(10):910-9. PubMed ID: 19326372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of multidrug resistance genes in normal and cancer stem cells.
    Shervington A; Lu C
    Cancer Invest; 2008 Jun; 26(5):535-42. PubMed ID: 18568776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular markers in circulating tumour cells from metastatic colorectal cancer patients.
    Gazzaniga P; Gradilone A; Petracca A; Nicolazzo C; Raimondi C; Iacovelli R; Naso G; Cortesi E
    J Cell Mol Med; 2010 Aug; 14(8):2073-7. PubMed ID: 20597995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway.
    Ma S; Lee TK; Zheng BJ; Chan KW; Guan XY
    Oncogene; 2008 Mar; 27(12):1749-58. PubMed ID: 17891174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nuclear-Biased DUSP6 Expression is Associated with Cancer Spreading Including Brain Metastasis in Triple-Negative Breast Cancer.
    Wu F; McCuaig RD; Sutton CR; Tan AHY; Jeelall Y; Bean EG; Dai J; Prasanna T; Batham J; Malik L; Yip D; Dahlstrom JE; Rao S
    Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31238530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo investigation of CD133 as a putative marker of cancer stem cells in Hep-2 cell line.
    Wei XD; Zhou L; Cheng L; Tian J; Jiang JJ; Maccallum J
    Head Neck; 2009 Jan; 31(1):94-101. PubMed ID: 18853445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. miR-130b Promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1.
    Ma S; Tang KH; Chan YP; Lee TK; Kwan PS; Castilho A; Ng I; Man K; Wong N; To KF; Zheng BJ; Lai PB; Lo CM; Chan KW; Guan XY
    Cell Stem Cell; 2010 Dec; 7(6):694-707. PubMed ID: 21112564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.